Published in FDA Law Weekly, May 26th, 2005
Approved on March 21, 2005, by the U. S. Food and Drug Administration (FDA), AcrySof ReSTOR is the first and only IOL that uses apodized diffractive technology to provide cataract patients with and without presbyopia a quality range of vision.
In clinical trials, 80% of patients reported "never" wearing reading glasses or bifocals following bilateral cataract surgery. The vast majority of patients who undergo...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of FDA Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.